Tiziana Life Sciences Doses More MS Patients in Expanded Access Program
Ticker: TLSA · Form: 6-K · Filed: Feb 18, 2025 · CIK: 1723069
Sentiment: neutral
Topics: clinical-trial, biotechnology, drug-development, patient-dosing
TL;DR
Tiziana Life Sciences is dosing more MS patients in their expanded access program, showing continued trial progress.
AI Summary
On February 18, 2025, Tiziana Life Sciences LTD announced the dosing of four additional patients in its Intermediate Size Patient Population Expanded Access (ISPPEA) program. This program is for patients diagnosed with non-active secondary progressive multiple sclerosis (na-SPMS) who do not meet the criteria for other trials.
Why It Matters
This expansion of the ISPPEA program indicates continued progress and patient enrollment in Tiziana's efforts to treat secondary progressive multiple sclerosis.
Risk Assessment
Risk Level: medium — The filing is a routine update on patient dosing, but the company operates in the highly speculative biotechnology sector, which carries inherent risks.
Key Players & Entities
- Tiziana Life Sciences LTD (company) — Registrant
- February 18, 2025 (date) — Filing Date
- Intermediate Size Patient Population Expanded Access (ISPPEA) (program) — Clinical Trial Program
- non-active secondary progressive multiple sclerosis (na-SPMS) (disease) — Target Patient Condition
FAQ
What is the purpose of the ISPPEA program?
The ISPPEA program is for patients with non-active secondary progressive multiple sclerosis (na-SPMS) who do not meet the criteria for other trials.
When was this update filed with the SEC?
This Form 6-K was filed on February 18, 2025.
How many additional patients were dosed?
An additional four patients were dosed in the ISPPEA program.
What is the company's primary business sector?
Tiziana Life Sciences LTD operates in the Pharmaceutical Preparations sector.
What is the company's principal executive office address?
The company's principal executive office is located at 9th Floor, 107 Cheapside, London EC2V 6DN.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on February 18, 2025 regarding Tiziana Life Sciences Ltd (TLSA).